BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

797 related articles for article (PubMed ID: 28674001)

  • 1. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses.
    Chew V; Lai L; Pan L; Lim CJ; Li J; Ong R; Chua C; Leong JY; Lim KH; Toh HC; Lee SY; Chan CY; Goh BKP; Chung A; Chow PKH; Albani S
    Proc Natl Acad Sci U S A; 2017 Jul; 114(29):E5900-E5909. PubMed ID: 28674001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-infiltrating FoxP3+ Tregs and CD8+ T cells affect the prognosis of hepatocellular carcinoma patients.
    Huang Y; Wang FM; Wang T; Wang YJ; Zhu ZY; Gao YT; Du Z
    Digestion; 2012; 86(4):329-37. PubMed ID: 23207161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD38 marks the exhausted CD8
    Reolo MJY; Otsuka M; Seow JJW; Lee J; Lee YH; Nguyen PHD; Lim CJ; Wasser M; Chua C; Lim TKH; Leow WQ; Chung A; Goh BKP; Chow PKH; DasGupta R; Yeong JPS; Chew V
    Front Immunol; 2023; 14():1182016. PubMed ID: 37377962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment.
    Syed Khaja AS; Toor SM; El Salhat H; Faour I; Ul Haq N; Ali BR; Elkord E
    Oncotarget; 2017 May; 8(20):33159-33171. PubMed ID: 28388539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory T cells, especially ICOS
    Tu JF; Ding YH; Ying XH; Wu FZ; Zhou XM; Zhang DK; Zou H; Ji JS
    Sci Rep; 2016 Oct; 6():35056. PubMed ID: 27725696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality.
    Kalathil S; Lugade AA; Miller A; Iyer R; Thanavala Y
    Cancer Res; 2013 Apr; 73(8):2435-44. PubMed ID: 23423978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma.
    Langhans B; Nischalke HD; Krämer B; Dold L; Lutz P; Mohr R; Vogt A; Toma M; Eis-Hübinger AM; Nattermann J; Strassburg CP; Gonzalez-Carmona MA; Spengler U
    Cancer Immunol Immunother; 2019 Dec; 68(12):2055-2066. PubMed ID: 31724091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analyses of regulatory T cell subsets in patients with hepatocellular carcinoma: a crucial role of CD25(-) FOXP3(-) T cells.
    Kakita N; Kanto T; Itose I; Kuroda S; Inoue M; Matsubara T; Higashitani K; Miyazaki M; Sakakibara M; Hiramatsu N; Takehara T; Kasahara A; Hayashi N
    Int J Cancer; 2012 Dec; 131(11):2573-83. PubMed ID: 22419479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the Immune Microenvironment in Hepatocellular Carcinoma.
    Yarchoan M; Xing D; Luan L; Xu H; Sharma RB; Popovic A; Pawlik TM; Kim AK; Zhu Q; Jaffee EM; Taube JM; Anders RA
    Clin Cancer Res; 2017 Dec; 23(23):7333-7339. PubMed ID: 28928158
    [No Abstract]   [Full Text] [Related]  

  • 10. Amphiregulin activates regulatory T lymphocytes and suppresses CD8+ T cell-mediated anti-tumor response in hepatocellular carcinoma cells.
    Yuan CH; Sun XM; Zhu CL; Liu SP; Wu L; Chen H; Feng MH; Wu K; Wang FB
    Oncotarget; 2015 Oct; 6(31):32138-53. PubMed ID: 26451607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased frequency of Foxp3+ regulatory T cells in mice with hepatocellular carcinoma.
    Du Y; Chen X; Huang ZM; Ye XH; Niu Q
    Asian Pac J Cancer Prev; 2012; 13(8):3815-9. PubMed ID: 23098476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective recruitment of regulatory T cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis.
    Chen KJ; Lin SZ; Zhou L; Xie HY; Zhou WH; Taki-Eldin A; Zheng SS
    PLoS One; 2011; 6(9):e24671. PubMed ID: 21935436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model.
    Li G; Liu D; Cooper TK; Kimchi ET; Qi X; Avella DM; Li N; Yang QX; Kester M; Rountree CB; Kaifi JT; Cole DJ; Rockey DC; Schell TD; Staveley-O'Carroll KF
    J Hepatol; 2017 Jan; 66(1):75-85. PubMed ID: 27520877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients.
    Fu J; Xu D; Liu Z; Shi M; Zhao P; Fu B; Zhang Z; Yang H; Zhang H; Zhou C; Yao J; Jin L; Wang H; Yang Y; Fu YX; Wang FS
    Gastroenterology; 2007 Jun; 132(7):2328-39. PubMed ID: 17570208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased liver-infiltrating CD8+FoxP3+ regulatory T cells are associated with tumor stage in hepatocellular carcinoma patients.
    Yang ZQ; Yang ZY; Zhang LD; Ping-Bie ; Wang SG; Ma KS; Li XW; Dong JH
    Hum Immunol; 2010 Dec; 71(12):1180-6. PubMed ID: 20870003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrahepatic interleukin-17+ T cells and FoxP3+ regulatory T cells cooperate to promote development and affect the prognosis of hepatocellular carcinoma.
    Huang Y; Wang F; Wang Y; Zhu Z; Gao Y; Ma Z; Xu R; Du Z
    J Gastroenterol Hepatol; 2014 Apr; 29(4):851-9. PubMed ID: 24303990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of Fas/FasL in CD8+ T and CD3+ Foxp3+ Treg cells--relationship with apoptosis of circulating CD8+ T cells in hepatocellular carcinoma patients.
    Guo CL; Yang XH; Cheng W; Xu Y; Li JB; Sun YX; Bi YM; Zhang L; Wang QC
    Asian Pac J Cancer Prev; 2014; 15(6):2613-8. PubMed ID: 24761872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Foxp3+ regulatory T cells are associated with the natural history of chronic hepatitis B and poor prognosis of hepatocellular carcinoma.
    Wang F; Jing X; Li G; Wang T; Yang B; Zhu Z; Gao Y; Zhang Q; Yang Y; Wang Y; Wang P; Du Z
    Liver Int; 2012 Apr; 32(4):644-55. PubMed ID: 22118340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of recurrence and survival in hepatocellular carcinoma based on two Cox models mainly determined by FoxP3+ regulatory T cells.
    Lin SZ; Chen KJ; Xu ZY; Chen H; Zhou L; Xie HY; Zheng SS
    Cancer Prev Res (Phila); 2013 Jun; 6(6):594-602. PubMed ID: 23599540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intratumoral regulatory T cells with higher prevalence and more suppressive activity in hepatocellular carcinoma patients.
    Wu H; Chen P; Liao R; Li YW; Yi Y; Wang JX; Cai XY; He HW; Jin JJ; Cheng YF; Fan J; Sun J; Qiu SJ
    J Gastroenterol Hepatol; 2013 Sep; 28(9):1555-64. PubMed ID: 23517245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.